CHRS
Price
$0.74
Change
+$0.01 (+1.37%)
Updated
Jun 27 closing price
Capitalization
86.15M
31 days until earnings call
RXRX
Price
$5.03
Change
-$0.37 (-6.85%)
Updated
Jun 27 closing price
Capitalization
2.04B
44 days until earnings call
Interact to see
Advertisement

CHRS vs RXRX

Header iconCHRS vs RXRX Comparison
Open Charts CHRS vs RXRXBanner chart's image
Coherus Oncology
Price$0.74
Change+$0.01 (+1.37%)
Volume$1.78M
Capitalization86.15M
Recursion Pharmaceuticals
Price$5.03
Change-$0.37 (-6.85%)
Volume$46.63M
Capitalization2.04B
CHRS vs RXRX Comparison Chart in %
Loading...
CHRS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RXRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CHRS vs. RXRX commentary
Jun 30, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CHRS is a Buy and RXRX is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 30, 2025
Stock price -- (CHRS: $0.74 vs. RXRX: $5.03)
Brand notoriety: CHRS and RXRX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CHRS: 126% vs. RXRX: 190%
Market capitalization -- CHRS: $86.15M vs. RXRX: $2.04B
CHRS [@Biotechnology] is valued at $86.15M. RXRX’s [@Biotechnology] market capitalization is $2.04B. The market cap for tickers in the [@Biotechnology] industry ranges from $304.6B to $0. The average market capitalization across the [@Biotechnology] industry is $2.3B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CHRS’s FA Score shows that 0 FA rating(s) are green whileRXRX’s FA Score has 0 green FA rating(s).

  • CHRS’s FA Score: 0 green, 5 red.
  • RXRX’s FA Score: 0 green, 5 red.
According to our system of comparison, RXRX is a better buy in the long-term than CHRS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CHRS’s TA Score shows that 3 TA indicator(s) are bullish while RXRX’s TA Score has 4 bullish TA indicator(s).

  • CHRS’s TA Score: 3 bullish, 4 bearish.
  • RXRX’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, RXRX is a better buy in the short-term than CHRS.

Price Growth

CHRS (@Biotechnology) experienced а -0.55% price change this week, while RXRX (@Biotechnology) price change was 0.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.13%. For the same industry, the average monthly price growth was +31.22%, and the average quarterly price growth was +12.91%.

Reported Earning Dates

CHRS is expected to report earnings on Jul 31, 2025.

RXRX is expected to report earnings on Aug 12, 2025.

Industries' Descriptions

@Biotechnology (+4.13% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RXRX($2.04B) has a higher market cap than CHRS($86.2M). RXRX YTD gains are higher at: -25.592 vs. CHRS (-46.152). CHRS has higher annual earnings (EBITDA): 80.2M vs. RXRX (-524.77M). RXRX has more cash in the bank: 500M vs. CHRS (82.4M). RXRX has less debt than CHRS: RXRX (92.9M) vs CHRS (270M). CHRS has higher revenues than RXRX: CHRS (272M) vs RXRX (59.8M).
CHRSRXRXCHRS / RXRX
Capitalization86.2M2.04B4%
EBITDA80.2M-524.77M-15%
Gain YTD-46.152-25.592180%
P/E Ratio1.68N/A-
Revenue272M59.8M455%
Total Cash82.4M500M16%
Total Debt270M92.9M291%
FUNDAMENTALS RATINGS
CHRS: Fundamental Ratings
CHRS
OUTLOOK RATING
1..100
76
VALUATION
overvalued / fair valued / undervalued
1..100
90
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
88
P/E GROWTH RATING
1..100
97
SEASONALITY SCORE
1..100
15

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
CHRSRXRX
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 3 days ago
79%
Bullish Trend 3 days ago
84%
Momentum
ODDS (%)
Bearish Trend 3 days ago
84%
Bearish Trend 3 days ago
87%
MACD
ODDS (%)
Bullish Trend 3 days ago
79%
Bullish Trend 3 days ago
83%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
89%
Bullish Trend 3 days ago
82%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
88%
Bullish Trend 3 days ago
84%
Advances
ODDS (%)
Bullish Trend 3 days ago
71%
N/A
Declines
ODDS (%)
Bearish Trend 17 days ago
88%
Bearish Trend 17 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
90%
Aroon
ODDS (%)
Bearish Trend 3 days ago
85%
Bearish Trend 3 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
CHRS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RXRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
OTCHX30.450.26
+0.86%
MFS Mid Cap Growth R3
BAFLX30.030.19
+0.64%
Brown Advisory Global Leaders Instl
IJEMX14.980.05
+0.33%
VY® JPMorgan Emerging Markets Equity I
CAPOX10.770.03
+0.28%
Absolute Capital Opportunities Instl
TRGMX21.410.01
+0.05%
Nuveen Quant Mid Cap Growth Retire